RUEIL-MALMAISON, France and TAIPEI, Taiwan, June 15, 2026 (GLOBE NEWSWIRE) — Schneider Electric, a global energy technology leader, today announced a strategic collaboration with Hon Hai Technology Group (Foxconn), the world’s largest electronics manufacturer, to help define and scale the next generation of AI data centers. As AI adoption surges, the demands on digital infrastructure are being fundamentally reshaped. This collaboration brings together Foxconn’s unmatched expertise in advanced compute platforms, AI rack integration, and global manufacturing with Schneider Electric’s leadership in power systems, cooling, and energy management. Together, the companies aim to deliver integrated, ready-to-deploy solutions that enable customers to build and operate AI infrastructure with greater speed, efficiency, and predictability...

BEIJING, June 15, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 40 clinical studies of the Company’s novel BTK inhibitor orelabrutinib were presented at the European Hematology Association (EHA) 2026 Congress. Clinical data on the efficacy and safety of orelabrutinib in treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients from the United States and Europe was released for the first time. A series of clinical studies on orelabrutinib covered multiple hematological malignancies, including CLL/SLL, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and primary central nervous system lymphoma (PCNSL)....

OSLO, Norway (15 June 2026) — Offshore wind market indicators remained subdued during the second quarter of 2026, while renewed focus on energy security is raising prospects for the industry’s recovery.  Released today, the latest quarterly Global Market Overview report from wind market intelligence house TGS | 4C notes that UK, France and Germany are among the countries that have accelerated renewable energy ambitions in attempts to lower reliance on imported energy. The latest outlook shows slightly lowered 2030 forecasts and moderately raised 2040 expectations for offshore wind, reflecting short-term delivery challenges but stronger long-term fundamentals. At the same time, the report notes that market conditions for offshore wind are improving on several fronts, supporting more consistent progression in 2026 and beyond. The global...

Please find attached the 2026 version of the Salmon Farming Industry Handbook. The handbook is also available on our website www.mowi.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.Attachment2026 Salmon Farming Industry Handbook

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) — Questerre Energy Corporation (“Questerre” or the “Company”) (TSX, OSE: QEC) reported successful results from a recent test of its HCCO® oil shale technology. The test was carried out at the PX Energy facility in southern Brazil. For the first time, the technology was tested in a full commercial-sized vessel, rather than the smaller lab-scale reactors used previously. The test is an important step aimed at improving the efficiency, reducing the cost, and improving the economics of the PX Energy project — and ultimately commercializing greenfield oil shale projects. This test was designed to prove the engineering and technical validity...

Perth, June 15, 2026 (GLOBE NEWSWIRE) — PERSEUS INCREASES ON-MARKET SHARE BUY-BACK TO A$150MILLION Perth, Western Australia/June 15, 2026/Perseus Mining Limited (ASX/TSX: PRU) is pleased to announce that on June 12, 2026, we have reached A$100 million of the A$100 million on-market share buyback announced in August 2025. Under this buyback, Perseus has purchased 19,077,751 shares at an average price of A$5.24 per share, of shares on issue at notification of the buyback on the 25 November 2025. In line with Perseus’s communicated Capital Allocation Framework to return capital to shareholders, the Perseus Board of Directors has approved an increase of A$50 million to this active on-market share buy-back programme to a total of A$150 million. Since the inception of the share buyback programmes in August 2024, Perseus has purchased...

Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignanciesROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China,...

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level Confirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients (

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase 1b/2a ACTH-dependent Cushing’s syndrome trial also presented, showing atumelnant rapidly lowered early morning cortisol and normalized urinary free cortisol levels even at lower dose SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented data today from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome. The findings were included in an oral presentation...

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks Additional ENDO highlights include long-term ACROBAT data demonstrating PALSONIFY and cabergoline combination improves biochemical control of acromegaly SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced new long-term data from its clinical development program evaluating novel PALSONIFYTM (paltusotine) in acromegaly during an oral presentation at the Endocrine Society’s Annual Meeting, ENDO 2026. Notably, pooled data from the open-label extension (OLE) trials of PATHFNDR-1 and PATHFNDR-2 show that after two years of treatment,...